Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03944369 · ClinicalTrials.gov registry record · NA
VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms
A NA study, sponsored by Kaleido Biosciences.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT03944369 is a NA study that was terminated before completion, run by Kaleido Biosciences. The registered enrollment target is 3 participants.
The verdict
NCT03944369, a NA study, was terminated before completion, sponsored by Kaleido Biosciences.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
This randomized, open-label, clinical study aims to explore the safety and tolerability of KB109, a novel glycan, versus an observational control group on the gut microbiome in subjects whose gastrointestinal tracts are colonized with multiple drug-resistant organisms.
Interventions
- OTHER No intervention
- OTHER KB109
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2020-06-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03944369
The ClinicalTrials.gov registry entry for NCT03944369 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaleido Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which No intervention is the first listed.
NCT03944369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03944369 about?
NCT03944369 is a clinical study titled "VITORA: Clinical Study to Evaluate the Effect of KB109 on the Gut Microbiome in Subjects Whose Gastrointestinal Tracts Are Colonized With Multiple Drug-resistant Organisms". This randomized, open-label, clinical study aims to explore the safety and tolerability of KB109, a novel glycan, versus an observational control group on the gut microbiome in subjects whose gastrointestinal tracts are colonized with multiple drug-resistant organisms.
What is the current status of trial NCT03944369?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2019-06-27. Estimated completion is 2020-06-16.
What interventions are being tested in trial NCT03944369?
The interventions under investigation include: No intervention (OTHER), KB109 (OTHER).
Who is sponsoring clinical trial NCT03944369?
This trial is sponsored by Kaleido Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.